Amedisys, Inc.

Informe Stock NasdaqGS:AMED

Capitalización de mercado: US$3.0b

Amedisys Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Amedisyshan disminuido a un ritmo medio anual de -13%, mientras que en la industria Healthcare los ingresos han sido de growing a 6.8% anuales. Los ingresos han sido growing a una tasa media anual de 5.2%.

Información clave

-13.0%

Tasa de crecimiento de los beneficios

-13.2%

Tasa de crecimiento del BPA

Crecimiento de la industria Healthcare 8.5%
Tasa de crecimiento de los ingresos5.2%
Rentabilidad financiera-1.0%
Margen neto-0.4%
Última actualización de beneficios31 Dec 2023

Actualizaciones de resultados anteriores recientes

Recent updates

Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 41% Discount?

Apr 10
Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 41% Discount?

Does Amedisys (NASDAQ:AMED) Have A Healthy Balance Sheet?

Feb 25
Does Amedisys (NASDAQ:AMED) Have A Healthy Balance Sheet?

Amedisys (NASDAQ:AMED) Will Be Hoping To Turn Its Returns On Capital Around

Feb 10
Amedisys (NASDAQ:AMED) Will Be Hoping To Turn Its Returns On Capital Around

At US$83.54, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

Jan 03
At US$83.54, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

A Look At The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Dec 16
A Look At The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Capital Allocation Trends At Amedisys (NASDAQ:AMED) Aren't Ideal

Nov 12
Capital Allocation Trends At Amedisys (NASDAQ:AMED) Aren't Ideal

Is Now The Time To Look At Buying Amedisys, Inc. (NASDAQ:AMED)?

Sep 19
Is Now The Time To Look At Buying Amedisys, Inc. (NASDAQ:AMED)?

An Intrinsic Calculation For Amedisys, Inc. (NASDAQ:AMED) Suggests It's 38% Undervalued

Sep 04
An Intrinsic Calculation For Amedisys, Inc. (NASDAQ:AMED) Suggests It's 38% Undervalued

Amedisys: ROIC, Tangible Book Value Each Softening

Aug 24

Slowing Rates Of Return At Amedisys (NASDAQ:AMED) Leave Little Room For Excitement

Aug 04
Slowing Rates Of Return At Amedisys (NASDAQ:AMED) Leave Little Room For Excitement

Amedisys profit beats by $0.24, revenue misses by $25.23M, 2022 guidance below estimates

Jul 27

We Think Amedisys (NASDAQ:AMED) Can Stay On Top Of Its Debt

Jul 20
We Think Amedisys (NASDAQ:AMED) Can Stay On Top Of Its Debt

At US$115, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

Jun 04
At US$115, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

Returns On Capital At Amedisys (NASDAQ:AMED) Have Stalled

May 05
Returns On Capital At Amedisys (NASDAQ:AMED) Have Stalled

Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 40% Discount?

Apr 20
Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 40% Discount?

Does Amedisys (NASDAQ:AMED) Deserve A Spot On Your Watchlist?

Apr 06
Does Amedisys (NASDAQ:AMED) Deserve A Spot On Your Watchlist?

Is Amedisys (NASDAQ:AMED) A Risky Investment?

Feb 20
Is Amedisys (NASDAQ:AMED) A Risky Investment?

Amedisys (NASDAQ:AMED) Shareholders Will Want The ROCE Trajectory To Continue

Jan 19
Amedisys (NASDAQ:AMED) Shareholders Will Want The ROCE Trajectory To Continue

Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?

Dec 03
Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?

These 4 Measures Indicate That Amedisys (NASDAQ:AMED) Is Using Debt Safely

Nov 18
These 4 Measures Indicate That Amedisys (NASDAQ:AMED) Is Using Debt Safely

Amedisys (NASDAQ:AMED) Could Easily Take On More Debt

Aug 18
Amedisys (NASDAQ:AMED) Could Easily Take On More Debt

Calculating The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Jul 23
Calculating The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Amedisys: Strategic Contessa Acquisition Underpins The Home Healthcare Growth Opportunity

Jul 18

Under The Bonnet, Amedisys' (NASDAQ:AMED) Returns Look Impressive

Jun 28
Under The Bonnet, Amedisys' (NASDAQ:AMED) Returns Look Impressive

It Looks Like Shareholders Would Probably Approve Amedisys, Inc.'s (NASDAQ:AMED) CEO Compensation Package

Jun 02
It Looks Like Shareholders Would Probably Approve Amedisys, Inc.'s (NASDAQ:AMED) CEO Compensation Package

Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?

May 24
Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?

Calculating The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Apr 14
Calculating The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Amedisys. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

NasdaqGS:AMED Ingresos, gastos y beneficios (USD Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
31 Dec 232,236-107800
30 Sep 232,22837740
30 Jun 232,22927890
31 Mar 232,2341127640
31 Dec 222,2231197540
30 Sep 222,2201217450
30 Jun 222,2161407360
31 Mar 222,2221917230
31 Dec 212,2142097110
30 Sep 212,2062201,0330
30 Jun 212,1962479110
31 Mar 212,1172027850
31 Dec 202,0721846680
30 Sep 202,0211662160
30 Jun 201,9721282140
31 Mar 201,9801272190
31 Dec 191,9561276080
30 Sep 191,8891272070
30 Jun 191,8121241970
31 Mar 191,7311231890
31 Dec 181,6631191850
30 Sep 181,626881810
30 Jun 181,583711780
31 Mar 181,546421780
31 Dec 171,511301770
30 Sep 171,474431810
30 Jun 171,456401870
31 Mar 171,438461900
31 Dec 161,419371960
30 Sep 161,391411980
30 Jun 161,358381930
31 Mar 161,313381880
31 Dec 151,266-31730
30 Sep 151,230-71580
30 Jun 151,204-71490
31 Mar 151,193-101420
31 Dec 141,188131470
30 Sep 141,191-41530
30 Jun 141,192-1031610
31 Mar 141,203-1091670
31 Dec 131,233-931700
30 Sep 131,278-1911760
30 Jun 131,340-901820

Ingresos de calidad: AMED actualmente no es rentable.

Margen de beneficios creciente: AMED actualmente no es rentable.


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: AMED no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 13% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de AMED en el último año con su media de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: AMED no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el del sector Healthcare (-0.6%).


Rentabilidad financiera

Alto ROE: AMED tiene un Rendimiento de los fondos propios negativo (-0.98%), ya que actualmente no es rentable.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target